Research Project

RP-2560 - TRIAL-GEN

Reforming Clinical TRIAL Eligibility for Improved GENeralisability – A Multifaceted-Study on EORTC Protocols, Investigator's Survey, Screening Data, and Real-world Evidence

Back to result

Project Status

Ongoing

Dates

Project start date: 18-Nov-2025

Type Data

Clinical Data

Type Research

Methodological research

Linked Studies

EORTC-24891

Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal squamous cell carcinoma ? A randomized phase III trial

EORTC-22931

Phase III randomized study on postoperative radio- and chemotherapy in patients with locally advanced head and neck carcinomas (Joint study of the EORTC Radiotherapy Cooperative Group and the Head and Neck Cancer Cooperative Group)

EORTC-26981-22981

"Concomitant and adjuvant Temozolomide and Radiotherapy for newly diagnosed glioblastoma multiforme. A randomized phase III study"

EORTC-90101

Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE")

EORTC-08111

A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC

EORTC-20051-LYMG

The H10 EORTC/GELA/IIL randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma.

EORTC-26053-22054

Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.

EORTC-18071

Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma : A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group.

EORTC-18081-MG

Adjuvant peginterferon alpha-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group

EORTC-1219

A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck

EORTC-1301-LG

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

EORTC-1307

A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients.

EORTC-1325-MG

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group

EORTC-1333-GUCG

A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

EORTC-1416-LCG

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy

EORTC-1420-HNCG-ROG

Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma

EORTC-1709-BTG

A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma - MIRAGE

EORTC-1976-STBSG-QLG-ETF

A 3 arm randomized study on healTh-related quality Of Life of EldeRly pAtients with advaNced soft tissue sarComa undergoing doxorubicin every three weeks or doxorubicin weekly or cyclophosphamide plus predniso(lo)ne treatment

EORTC-2139-MG

Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group